(2018) Histopathology 72, 259-269. https://doi.org/10.1111/his.13339 CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients Aims: CD274 (PDL1) and JAK2 (9p24.1) gene amplifications have been recently described in pulmonary carcinomas in association with programmed death-ligand 1 (PD-L1) expression. Furthermore, PTEN loss has been explored preclinically in relation to PD-L1 expression. Our aim was to determine whether these genomic alterations affect PD-L1 expression levels in non-small-cell lung cancer. Methods and results: PD-L1 and PTEN expression determined by immunohistochemistry (IHC), and CD274, JAK2 and PTEN copy number alterations (CNAs) determined by fluorescence in-situ hybridisation, were studied in 171 pulmonary carcinoma specimens. PD-L1 expression was positive in 40 cases (23.3%), and CD274 amplification was present in 14 tumours (8.8%). Concordance between both events was found in 12 of 14 amplified cases (P = 0.0001). We found nine JAK2-amplified cases (5.7%), seven with PD-L1 expression (P = 0.0006). Moreover, six of the seven cases had JAK2 and CD274 coamplification (9p24.1 genomic amplification). Remarkably, the average PD-L1 IHC score was higher in these amplified cases (230 versus 80; P = 0.001). Non-statistical associations were observed between PD-L1 expression and PTEN loss and PTEN deletions. Conclusions: We describe a subset of patients (8.2%) who had 9p24.1 amplifications resulting in high expression of PD-L1. Our results provide evidence for genomic up-regulation of PD-L1 expression in nonsmall-cell lung cancer.
Introduction
The immune system is able to recognise neoantigens generated by tumour cells, and potentially activate control responses. 1 However, these immune responses might be ineffective, because cancer cells can develop multiple escape mechanisms. 2, 3 Immune checkpoints, which are inhibitory signalling pathways that can down-modulate T-cell responses, constitute one of the key mechanisms of tumour evasion. The best-characterised immune checkpoints are cytotoxic T-lymphocyte antigen 4 and programmed death receptor 1 (PD-1), and their modulation through inhibitory antibodies has represented a major breakthrough in the treatment of melanoma and lung cancer, among other malignant tumours. 4 Currently, there are three available PD-1/ programmed death-ligand 1 (PD-L1) inhibitors for squamous non-small-cell lung cancer (NSCLC) and non-squamous NSCLC patients: nivolumab, pembrolizumab, and atezolizumab. [5] [6] [7] [8] PD-L1 expression on tumour and/or tumour-infiltrating lymphocytes (TILs) detected by immunohistochemistry (IHC), as performed in the clinical trials, is the most widely accepted predictive biomarker. However, the identification of PD-L1-negative patients who respond to therapy, 9, 10 and show long-term benefit from nivolumab and pembrolizumab, 11, 12 as well as PD-L1-positive patients who do not respond as expected, calls into question the reliability of PD-L1 expression as a sole predictive biomarker.
Biologically, PD-L1 expression can be induced by interferon (IFN)-c secreted from TILs, which suggests an adaptive feedback response to immune attack. 13, 14 However, in some settings, expression of PD-L1 is innate, and it is neither associated with TILs nor induced by IFN-c. 15 Constitutive tumour alterations, mostly associated with gene amplification and/or up-regulation of carcinogenetic-related pathways, are known to modulate PD-L1 expression. 15, 16 It has been shown that NSCLCs harbouring activating epidermal growth factor receptor (EGFR) mutations and ALK fusions have increased PD-L1 expression via STAT3, phosphoinositide 3-kinase (PI3K) or extracellular signal-regulated kinase transcript activation. 17, 18 In addition, as the PI3K-AKT signalling pathway is negatively regulated by PTEN, it is feasible that PTEN loss triggers an increase in PD-L1 expression, as shown in preclinical studies. 19, 20 Another mechanism, as previously seen in Hodgkin and mediastinal large B-cell lymphomas, is selective amplication of the 9p24.1 chromosomal region, which contains CD274 (PDL1), PDCD1LG2 (PDL2), and JAK2. 21 In addition, recent studies have revealed that there is a subgroup of NSCLC patients with simultaneous amplification of CD274 and JAK2 in association with PD-L1 expression, but the prevalence and significance of this alteration remain to be elucidated. 22, 23 Our study aimed to analyse 9p24.1 genomic alterations (CD274 and JAK2) and PTEN losses in correlation with PD-L1 expression in a pulmonary adenocarcinoma (ADC) and squamous-cell carcinoma (SCC) western population.
Materials and methods

P A T I E N T S E L E C T I O N
This retrospective study was conducted in a surgical cohort of 143 pulmonary carcinoma patients-93 ADCs and 50 SCCs-constructed in eight tissue microarrays (TMAs). 24 Between 2009 and 2015, we selected all pulmonary ADC and SCC patients with availability of additional tumour tissue from the same tumour sample previously used for histological and molecular diagnosis. A total of six tissue cores with diameters of 2 mm were obtained from each patient, four of them containing different histological areas of the carcinoma (named A, B, C, and D), and two of them containing benign lung parenchyma. In the present study, we analysed only two tumour cores (A and B). We extracted from medical records the molecular data concerning routinely analysed alterations: KRAS and EGFR mutations and ALK rearrangements in ADC samples, and FGFR1 amplifications in SCC samples. In addition to this TMAs cases, we selected 28 whole-tissue sections of ADC patients with advanced-stage disease to enrich for KRAS, EGFR and ALK molecular alterations not well represented in the TMAs. After this selection, we reached a 28%, 19% and 2% of KRAS, EGFR and ALK alterations, respectively. All biological samples were obtained from Parc de Salut MAR Biobank (MARBiobanc), Barcelona. This project was approved by the local ethics committee (ID: 2015/6336/I), and all patients provided written informed consent.
IHC was performed with the commercially available PD-L1 SP142 rabbit monoclonal antibody (Ventana, Tucson, AZ, USA) on unstained 4-lm formalin-fixed paraffin-embedded (FFPE) tissue sections from TMAs and whole-tissue samples, on an automated Benchmark XT immunostainer (Ventana). Antigen retrieval was performed for 32 min with CC1, and the antibody was applied manually for 80 min at 37°C. Signal visualisation was achieved with the Optiview DAB IHC Detection and Amplification kits (Ventana). IHC slides were evaluated independently by two wellexperienced pathologists (L.P. and J.G.) without any prior information on the clinicopathological features of the patient samples. Percentages of PD-L1-positive tumour cells and staining intensity were evaluated for each sample. The cut-off for positivity was set at ≥1%. 8 Moreover, a semiquantitative IHC approach was used to generate a score from 0 to 300. Briefly, staining intensity was scored as follows: 0, negative or trace; 1, weak; 2, moderate, and 3, high. The percentage of stained cells (0-100%) was multiplied by the dominant intensity pattern. 
P T E N P R O T E I N L O S S D E T E R M I N E D B Y I H C
Immunohistochemical analysis of PTEN was carried out on unstained FFPE 4-lm tissue sections of TMAs and whole-tissue samples, with the primary anti-PTEN Dako monoclonal mouse clone 6H2.1 and the Dako Envision+ System-HRP (Agilent Technologies, Santa Clara, CA, USA). The following scoring system was applied: 0, loss of expression; 1+, low homogeneous expression; and 2+, intense homogeneous expression. Adjacent normal tissue was used as an internal reference point for intensity scoring.
T I L s E V A L U A T I O N
Histopathological assessment of TILs was performed qualitatively (intense/non-intense) on representative haematoxylin and eosin (H&E)-stained sections of the TMAs and the whole-tissue biopsies, according to criteria published recently by Brambilla et al. TILs were evaluated within the tumour cell nests or in direct contact with the tumour cells (including the invasive borders). 26 Areas of in-situ carcinomas, necrosis and crush artefacts were not included.
S T A T I S T I C A L A N A L Y S I S
The whole series of cases was analysed in order to characterise clinicopathological associations. The average value between the two scoring pathologist was used for analysis, and the intraclass correlation coefficient (ICC) was calculated to show their interobserver concordance. Moreover, for TMA cases, the average value between the two cores was calculated. 
Results
C L I N I C A L A N D P A T H O L O G I C A L C H A R A C T E R I S T I C S O F T H E S T U D Y P O P U L A T I O N
Samples from 171 pulmonary carcinoma patients were analysed (Table 1) . Most of the samples showed moderate or poor histological differentiation (grades 2-3). The predominant histological patterns in ADCs were acinar or solid with mucin production, whereas lepidic and micropapillary patterns were less common.
With the current Ventana antibody PD-L1 IHC cut-off (≥1% at any intensity), 40 of 171 cases were positive (23.3%), with an average semiquantitative IHC score of 177. There were no discordant PD-L1 IHC-positive cases between both evaluating pathologists, and the ICC was 0.969. According to histology, there were no significant differences in expression between ADCs (29/121, 24%; average IHC score, 142) and SCCs (11/50, 22%; average IHC score, 102). PD-L1 positivity showed significant associations with an ADC solid EGFR, epidermal growth factor receptor; NA, not applicable; TILs, tumour-infiltrating lymphocytes. *Numbers in parentheses represent the specific populations (first parentheses, the ADC population; second, the SCC population; and third, the PD-L1-positive population) with available histological and molecular information.
histological pattern (P = 0.012), ADC KRAS mutations (P = 0.001), the presence of TILs (P = 0.001), and active smoking status (P = 0.031) ( Table 1) .
FISH results were evaluable in 159 of 171 cases (92.9%), as 12 cases were non-assessable because of FISH assay failure (absence or inconclusive hybridisation probe signals). We found 14 tumours with CD274 amplification (8.8%), with a mean of 6.7 gene copies (range 5-10) and a mean CD274/CEP9 ratio of 2.7 (range 2-4). Eleven of these 14 amplified tumours were ADCs (9%), and three were SCCs (6%). Moreover, 54 cases (34%) showed copy number gains owing to chromosome 9 polysomy, with a mean CD274/CEP9 ratio of <2: 21 tumours (13%) had high gene gains, and 33 (20.8%) had gains ( Figure 1 ). CD274-amplified tumours showed significant associations with ADC KRAS mutations (P = 0.029) and the presence of TILs (P = 0.002).
C O R R E L A T I O N B E T W E E N P D -L 1 A S S E S S M E N T B Y I H C A N D F I S H
CD274 amplification was associated with PD-L1 expression (P = 0.0001). CD274 amplification, and 16 had CD274 gains or high gains (Table 2) . Regarding FISH analysis, 12 of 14 amplified cases had positive PD-L1 expression.
Thus, CD274 amplification detected by FISH predicted a positive PD-L1 IHC result with a sensitivity of 31.6% and a specificity of 98.6%. 
JAK2 amplification
Positive PD-L1 IHC CD274 amplification JAK2 disomic Figure 3 . Examples of programmed death-ligand 1 expression in cases harbouring CD274 (PDL1) amplification. Case A showed selective amplification of 9p24.1, which contains CD274 and JAK2 (PDJ amplicon). Case B had only CD274 amplification with disomic JAK2.
J A K 2 C H A R A C T E R I Z A T I O N A C C O R D I N G T O P D -L 1 E X P R E S S I O N
We examined JAK2 CNAs in all cases to determine the prevalence of amplifications in realtion to to PD-L1 expression. We found nine JAK2-amplified cases (9/ 159; 5.7%), seven with PD-L1 expression (P = 0.0006). Six of the seven cases had JAK2 and CD274 coamplification (9p24.1 amplification), and only one case showed JAK2 amplification alone (2.5%) (Figures 2 and 3) . Globally, 13 of 159 FISH-evaluable cases (8.2%) had gene amplifications resulting in high expression of PD-L1. In the clinical setting, no significant differences were observed between cases with CD274 amplification alone and coamplified cases (Table 3) . However, tumours with CD274 and/or JAK2 amplification had a three-fold increase in PD-L1 expression as compared with cases lacking amplifications of 9p24.1 (average IHC score: 230 versus 80; P = 0.001).
P T E N C H A R A C T E R I Z A T I O N A C C O R D I N G T O P D -L 1 E X P R E S S I O N
PTEN IHC results were evaluable in 158 of 171 cases (92.4%). Loss of PTEN expression was found in 50 cases (50/158; 31.6%), 16 of them with PD-L1 expression, without a statistical association (P = 0.06). We further analysed PTEN CNAs by FISH in the whole series, with 119 assessable samples (69.6%). We identified 20 PTEN-deleted cases, all with heterozygous deletion (20/119; 16.8%), and eight of them with PD-L1 expression (P = 0.074) ( Table 4 ). There was no correlation between loss of PTEN expression and heterozygous PTEN deletion (k = 0.289) ( Table 5) . Examples of PTEN IHC scoring and CNA FISH patterns in PD-L1-positive cases are shown in Figure 4 .
Discussion
We report associations between PD-L1 expression and CD274 (PDL1) and JAK2 amplifications in pulmonary SCC and ADC patients. We describe a subset of patients (8.2%) who had 9p24.1 amplifications resulting in high expression of PD-L1. Our results provide evidence for genomic up-regulation of PD-L1 expression in NSCLC. Patient's clinical characteristics and tumour biology are known to affect the PD-1/PD-L1 immune checkpoint. Parsa et al. reported that PD-L1 expression is up-regulated by key oncogenic pathways, such as the PI3K-AKT and RAS-RAF-mitogen-activated protein kinase pathways. 27 We found that PD-L1 Table 3 . Clinical features of CD274 and CD274-JAK2 amplified cases in PD-L1 positive subset of patients. Both groups had a higher PD-L1 IHC expression score than tumours without copy number alteration (CNAs) (P = 0.001) expression was significantly more prevalent in KRASmutated ADCs, as previously described. 28, 29 We also found increased PD-L1 expression in current and former smokers, as smoking-associated lung cancers have been described as having a higher mutational load, resulting in the generation of more tumour neoantigens and increasing immunogenicity. 30, 31 Finally, we found that stromal TIL infiltration was also significantly associated with PD-L1 expression, in agreement with previous reports. 32, 33 Previous studies investigating CD274 CNAs have found that there is a subgroup of patients with primary NSCLC who harbour gene amplifications. First, Ikeda et al. found five of 94 (5.3%) surgically resected NSCLCs (pooling together both SCCs and ADCs) with CD274 amplification, by using real-time polymerase chain reaction as a screening method. They did not find any correlation between PD-L1 expression level and gene amplification, although the in-vitro assays suggested that the induction of PD-L1 expression by inflammatory cytokines was more efficient in cancer cells harbouring CD274 amplifications. 22 Later, Goldmann et al. analysed CD274 CNAs by FISH, and found 11 of 221 cases (4.9%) with amplification, all of them with positive PD-L1 immunohistochemical expression. 34 The FISH criterion for amplified cases (named 'copy number gains' in their publication) was the same as we have presented here (mean CD274/ CEP9 ratio of ≥2.0). Recently, Inoue et al. reported a larger series (n = 654) of surgically treated NSCLC (SCC and ADC) patients in whom CD274 and PDCD1LG2 (PDL2) were analysed by FISH. They found 20 of 654 cases (3.1%) with CD274 amplification, and 84 (13.2%) with chromosome 9 polysomy, reporting that the increase in CD274 copy number was associated with PD-L1 expression. 23 The definition of gene amplification in this publication was also in accordance with ours. Although we used the same method and criterion as Inoue et al., our higher prevalence rates of CD274 amplification (8.8% versus 3.1%) and polysomy/gains (34% versus 13.2%) may be attributable to differences in ethnic and molecular characteristics between the patient cohorts.
Analysis of JAK2 amplifications revealed that patients with 9p24.1 amplification (involving both CD274 and JAK2) had almost three-fold increased PD-L1 expression as compared with patients with PD-L1 expression without amplification. These results might suggest that enhancement of JAK-STAT signalling through JAK2 amplification, in addition to amplification of CD274 itself, further increases PD-L1 expression. 21, 22 As there are different patterns of 9q24.1 amplification, involving or not involving CD274 and JAK2, resulting in different PD-L1 expression levels, copy number gene analysis might complement PD-L1 IHC studies. Even so, three cases in our PD-L1-negative cohort had 9p24.1 amplification (CD274 and/or JAK2). This discrepancy may be attributable to PD-L1 up-regulation mechanisms being multifactorial and not mutually exclusive. The heterogeneity of PD-L1 expression within the tumours may also have contributed to the discrepancy. 36 Loss of PTEN expression is a frequent event in NSCLC, although genetic alterations in PTEN are rare in this setting. 37 None of the cases with loss of PTEN expression in our series showed consequent homozygous deletion, which suggests that PTEN inactivation may be explained by other genetic or epigenetic changes. Moreover, we could not find any correlation between the expression levels of PD-L1 and PTEN in our cohort, in accordance with recent analyses of PTEN-PI3K pathways in malignant pleural mesothelioma. 38 In summary, CD274 (PDL1) CNAs are present in SCC and ADC western populations, and gene amplification is associated with PD-L1 expression. Moreover, JAK2 is frequently coamplified with CD274, and this defines a subset of patients who had 9p24.1 amplifications resulting in higher expression of PD-L1. These CNAs could give us information about tumour biology in PD-L1 positive patients. Further clinical studies in CD274 amplified patients treated with immunotherapy might be considered.
